Skip to content

Study · Case report or series · n = 1 · 2026

5 results

Clinical Improvements with Setmelanotide in a 2-Year-Old Patient with Hyperphagia and Obesity due to Leptin Receptor Deficiency: A Case Report.

Pons MR, Gutierrez Vilar M, Rodriguez AP, Alonso JM

Obesity facts27 Mar 2026

PMID41894554 (opens in a new tab)PMCIDPMC13249433 (opens in a new tab)DOI10.1159/000551601 (opens in a new tab)PepBankPUB-41894554
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a child with LEPR deficiency, setmelanotide treatment was followed by reductions in hyperphagia, food intake, cravings and BMI.

    In plain wordsIn a child with LEPR deficiency, hunger, food intake, cravings and BMI decreased after setmelanotide began.

    Peptide
    Setmelanotide
    Outcome
    DecreaseHyperphagia, food intake, cravings and BMI
    Study

    n = 1

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.5 mg/day increased to 2.5 mg/day in 0.5 mg increments · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Following treatment initiation, significant clinical improvements were observed, including reductions in hyperphagia, food intake and cravings, and body mass index (BMI).
    2 context sentences
    Summary · context
    This case report describes the use of setmelanotide in a 2-year-old child with hyperphagia and obesity due to LEPR deficiency.
    Summary · context
    Setmelanotide treatment via subcutaneous injection was initiated in March 2023 (patient age 2 years 4 months) at a dose of 0.5 mg/day, increased to 2.5 mg/day in 0.5 mg increments, and the patient was followed for 23 months.
  2. 02HumanCase report or seriesEfficacy outcome

    In a child with LEPR deficiency receiving setmelanotide, motor function improved, including crawling and kneeling milestones.

    In plain wordsIn a child receiving setmelanotide, motor skills improved, including crawling and kneeling.

    Peptide
    Setmelanotide
    Outcome
    IncreaseMotor function
    Study

    n = 1

    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    0.5 mg/day increased to 2.5 mg/day in 0.5 mg increments · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Motor skill function also improved, with the child achieving milestones such as crawling and kneeling.
    2 context sentences
    Summary · context
    This case report describes the use of setmelanotide in a 2-year-old child with hyperphagia and obesity due to LEPR deficiency.
    Summary · context
    Setmelanotide treatment via subcutaneous injection was initiated in March 2023 (patient age 2 years 4 months) at a dose of 0.5 mg/day, increased to 2.5 mg/day in 0.5 mg increments, and the patient was followed for 23 months.
  3. 03HumanCase report or seriesSafety outcome

    A child with LEPR deficiency receiving setmelanotide developed skin rash.

    In plain wordsA child receiving setmelanotide developed skin rash.

    Peptide
    Setmelanotide
    Outcome
    Not applicableSkin rash
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    0.5 mg/day increased to 2.5 mg/day in 0.5 mg increments · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Reported adverse events included skin rash and skin hyperpigmentation.
    2 context sentences
    Summary · context
    This case report describes the use of setmelanotide in a 2-year-old child with hyperphagia and obesity due to LEPR deficiency.
    Summary · context
    Setmelanotide treatment via subcutaneous injection was initiated in March 2023 (patient age 2 years 4 months) at a dose of 0.5 mg/day, increased to 2.5 mg/day in 0.5 mg increments, and the patient was followed for 23 months.
  4. 04HumanCase report or seriesSafety outcome

    A child with LEPR deficiency receiving setmelanotide developed skin hyperpigmentation.

    In plain wordsA child receiving setmelanotide developed darker skin.

    Peptide
    Setmelanotide
    Outcome
    IncreaseSkin hyperpigmentation
    Study

    n = 1

    Outcome group
    Pigmentation · Skin and wound
    Studied dose
    0.5 mg/day increased to 2.5 mg/day in 0.5 mg increments · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Reported adverse events included skin rash and skin hyperpigmentation.
    2 context sentences
    Summary · context
    This case report describes the use of setmelanotide in a 2-year-old child with hyperphagia and obesity due to LEPR deficiency.
    Summary · context
    Setmelanotide treatment via subcutaneous injection was initiated in March 2023 (patient age 2 years 4 months) at a dose of 0.5 mg/day, increased to 2.5 mg/day in 0.5 mg increments, and the patient was followed for 23 months.
  5. 05HumanCase report or seriesEfficacy outcome

    Caregivers of a child with LEPR deficiency receiving setmelanotide reported significant quality-of-life improvements.

    In plain wordsCaregivers reported improved quality of life while the child received setmelanotide.

    Peptide
    Setmelanotide
    Outcome
    Not applicableCaregiver quality of life
    Study

    n: not reported in source

    Outcome group
    Quality of life · Whole body
    Studied dose
    0.5 mg/day increased to 2.5 mg/day in 0.5 mg increments · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Significant improvements in caregivers' QoL were also reported.
    2 context sentences
    Summary · context
    This case report describes the use of setmelanotide in a 2-year-old child with hyperphagia and obesity due to LEPR deficiency.
    Summary · context
    Setmelanotide treatment via subcutaneous injection was initiated in March 2023 (patient age 2 years 4 months) at a dose of 0.5 mg/day, increased to 2.5 mg/day in 0.5 mg increments, and the patient was followed for 23 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.